22 July 2021 
EMA/CHMP/398036/2021  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion 1 (post authorisation) 
Volibris 
ambrisentan 
On 22 July 2021,  the Committee for Medicinal  Products for Human Use (CHMP)  adopted a positive opinion 
recommending a change to  the terms of the marketing authorisation for the medicinal product Volibris. 
The marketing authorisation holder for this  medicinal product is GlaxoSmithKline (Ireland) Limited. 
The CHMP introduced a new strength (2.5  mg film coated tablets)  and adopted an extension to  the 
existing indication as follows: 2  
Volibris is indicated for treatment of pulmonary arterial hypertension (PAH) in adult  patients of 
WHO Functional  Class (FC) II to III, including use in combination treatment  (see section 5.1). 
Efficacy has been shown in  idiopathic PAH (IPAH) and in  PAH associated with connective tissue 
disease. 
Volibris is indicated for treatment  of PAH in adolescents and  children (aged 8 to less 
than  18 years)  of WHO  Functional Class (FC)  II to III including use in combination 
treatment.  Efficacy has been  shown in IPAH, familial, corrected congenital and in PAH 
associated with connective tissue disease  (see section 5.1). 
Detailed recommendations for the use of this  product will be described in the updated summary of 
product characteristics (SmPC), which will  be published in the  revised European public assessment report 
(EPAR), and will be available in all official European Union  languages after a decision on this change to 
the marketing authorisation has been granted by the  European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European  Union   
© European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
